+34 917081076 Calle Gobelas 17, planta 1, 28023 Madrid (Spain)New compounds and services for Pharma industry

Category Announcements

Apr
10
2013

Novel Cancer Target

Plebiotic SL (Madrid, Spain) and Pharmacellion Ltd (Wirral, UK) have completed a research project on the modelling, structural analysis and molecular dynamics of several Pharmacellion compounds designed to inhibit target protein Na K ATPase, a novel cancer target. The study confirms that all six Pharmacellion compounds studied using the Plebiotic “PleMD” platform bind to their […]

Apr
1
2013

Two new products launched

Plebiotic has launched two new products targeted at drug discovery. In combination with PleMD product (Molecular Dynamics), it is the perfect platform for drug repositioning. The two products launched are: Gambit (Reverse docking): With reverse docking, given a ligand, we look for other targets suited for it. Clearly has a direct application on drug repositioning. At Plebiotic we have created […]

Feb
1
2013

i-deals collaboration

Plebiotic and i-deals have signed a collaboration agreement for which i-deals will do the commercialisation of Plebiotic product portfolio and services. This agreement is a renewal of a former collaboration agreement between both companies. i-deals (part of the everis Group, which has 30 offices around the world, including in the US: Boston, Washington D.C. and Alabama) is […]